A review of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) against other 52-week high stocks is provided. With the US Federal Reserve cutting rates, a shift in the investment landscape is observed. While HRMY shows promising financials, its dependency on one product poses risks.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing